Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 February 2020 | Story Xolisa Mnukwa | Photo Sonia Small
T-systems funding
Opening the doors of opportunity – TSSA allocated R2,4 million in bursary funding for 200 UFS students.


It is no secret that higher education institutions all over South Africa are plagued with the burden of current and historical student debt, leaving many hopeful students with the risk of financial exclusion. T-Systems South Africa (TSSA) has contributed a substantial amount of R2,4 million to fund a total of 200 students at the University of the Free State (UFS) in order to address ‘skills shortages’ in South Africa.

TSSA, a local unit of T-Systems International – a subsidiary of Deutsche Telekom – is invested in capitalising on South African expertise where innovation and intellectual property of a global (Information and Communications Technology) ICT provider is involved. The company strives to transform their clients and South Africa as a whole by providing innovative ICT solutions that work, in South Africa and for South Africa.

The company aims to endorse inclusive transformation in South Africa through the promotion and implementation of skills and enterprise development, as well as job creation. This forms part of the company’s National Development Plan for 2030 that envisions the elimination of poverty and reduced inequality.

Kovsie Alumni Trust Investment

Through its corporate social-responsibility wing called the Nation Building Initiative, T-Systems identified the University of the Free State after being contacted by the Kovsie Alumni Trust (KAT). 

KAT identified this opportunity as a call for the university to aid the advancement of students through initiatives such as the Integrated Transformation Plan (ITP), which was first launched in 2017. The ITP aims to utilise the university’s core functions (routed in teaching and learning, research, and engaged scholarship) to train and mould students into globally competitive graduates, which essentially also build towards skills and enterprise development, together with job creation. 

“The contribution of funding from T-Systems enabled us to empower our honours students by paying their outstanding university debt for 2019.  This has had a significant impact on the lives of many of our honours students who will be able to enrol for master’s programmes or seek employment without the burden of university debt,” says Professor Corli Witthuhn, UFS Vice-Rector: Research, Innovation and Internationalisation. 

“The University of the Free State is looking forward to partnering with T-Systems in 2020 in order to ensure continued opportunities for our students to further their education.”


Addressing a skills shortage in South Africa

Kovsie students completing honours studies in fields such as technology, human resources, and marketing as well as qualifications routed in accounting and finance, were given preference for the bursary. Other senior students required a pass mark of 60% or more to qualify for the bursary. TSSA paid off the university debt of students selected in 2019, and they had the opportunity to reapply in 2020. The UFS Alumni office facilitated the process. 

In 2020, students from all study years will be considered for the bursary, including matriculants who are entering university for the first time.  

Dineo Molefe , Managing Director at TSSA, says: “T-Systems has always invested in education by running a number of developmental initiatives, among others its ICT Academy – which provides free learnerships, internship programmes, including a learnership for disabled people as well as the flagship Hazyview Digital Learning Centre, which has become a unique rural nearshoring success story.

“All of this is earmarked to address the serious shortage of ICT skills – and by developing those skills, we not only address an industry problem but also contribute to employment opportunities in South Africa.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept